Perceptive Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Perceptive Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,185,632	Closed	-$21.7M	–	96
2025 Q4	$21.7M	Sell	4,185,632 -1,036,679	-20%	-$5.33M	0.39%	59
2025 Q3	$27.3M	Buy	5,222,311 +1,170,680	+29%	+$6.1M	0.79%	36
2025 Q2	$15.5M	Sell	4,051,631 -5,224,220	-56%	-$13.5M	0.58%	42
2025 Q1	$53.3M	Hold	9,275,851	–	–	1.88%	11
2024 Q4	$46.3M	Hold	9,275,851	–	–	1.28%	25
2024 Q3	$50M	Hold	9,275,851	–	–	1.06%	29
2024 Q2	$30.7M	Buy	9,275,851 +682,265	+8%	+$2.67M	0.74%	42
2024 Q1	$28.1M	Hold	8,593,586	–	–	0.49%	58
2023 Q4	$30.2M	Sell	8,593,586 -2,756,499	-24%	-$8.51M	0.67%	42
2023 Q3	$75.8M	Hold	11,350,085	–	–	2.53%	10
2023 Q2	$95.2M	Hold	11,350,085	–	–	2.76%	7
2023 Q1	$113M	Hold	11,350,085	–	–	3.33%	9
2022 Q4	$79M	Hold	11,350,085	–	–	2.22%	14
2022 Q3	$60.6M	Buy	11,350,085 +1,446,206	+15%	+$8.68M	1.76%	15
2022 Q2	$39.5M	Hold	9,903,879	–	–	1.24%	21
2022 Q1	$44M	Hold	9,903,879	–	–	0.88%	30
2021 Q4	$39.6M	Hold	9,903,879	–	–	0.61%	43
2021 Q3	$87M	Hold	9,903,879	–	–	1.26%	21
2021 Q2	$112M	Buy	9,903,879 +1,200,000	+14%	+$14.4M	1.46%	19
2021 Q1	$103M	Buy	8,703,879 +2,418,421	+38%	+$27.8M	1.31%	22
2020 Q4	$43.1M	Hold	6,285,458	–	–	0.46%	51
2020 Q3	$46.6M	Buy	6,285,458 +3,200,000	+104%	+$20.7M	0.68%	40
2020 Q2	$12.9M	Hold	3,085,458	–	–	0.21%	73
2020 Q1	$7.62M	Hold	3,085,458	–	–	0.2%	67
2019 Q4	$17.9M	Hold	3,085,458	–	–	0.36%	51
2019 Q3	$16.3M	Hold	3,085,458	–	–	0.44%	47
2019 Q2	$18.5M	Hold	3,085,458	–	–	0.42%	50
2019 Q1	$27.9M	Hold	3,085,458	–	–	0.79%	32
2018 Q4	$24.7M	Hold	3,085,458	–	–	0.94%	29
2018 Q3	$42.6M	Hold	3,085,458	–	–	1.14%	28
2018 Q2	$24.5M	Hold	3,085,458	–	–	0.64%	43
2018 Q1	$23.1M	Hold	3,085,458	–	–	0.65%	39
2017 Q4	$21M	Hold	3,085,458	–	–	0.7%	37
2017 Q3	$22.2M	Buy	3,085,458 +200,000	+7%	+$1.04M	0.85%	27
2017 Q2	$13.4M	Hold	2,885,458	–	–	0.68%	41
2017 Q1	$12.9M	Buy	2,885,458 +945,000	+49%	+$4.87M	0.73%	35
2016 Q4	$10.4M	Hold	1,940,458	–	–	0.74%	33
2016 Q3	$15.2M	Hold	1,940,458	–	–	0.98%	25
2016 Q2	$11M	Buy	1,940,458 +700,000	+56%	+$3.91M	0.77%	29
2016 Q1	$5.2M	Hold	1,240,458	–	–	0.46%	55
2015 Q4	$8.41M	Buy	1,240,458 +283,265	+30%	+$1.9M	0.62%	39
2015 Q3	$5.58M	Buy	957,193 +87,393	+10%	+$683K	0.45%	52
2015 Q2	$6.75M	Buy	869,800 +512,800	+144%	+$4.42M	0.41%	55
2015 Q1	$3.63M	Buy	+357,000	New	+$3.64M	0.28%	65

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors's ALDX Position: Q1 2026 in Review

Perceptive Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 4,185,632 shares — an estimated $21.7M sold.

Perceptive Advisors first reported a position in ALDX in Q1 2015 and held it in 44 quarters. The position peaked at $113M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Perceptive Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
Perceptive Advisors sold 4,185,632 Aldeyra Therapeutics shares in Q1 2026, an estimated $21.7M.
Perceptive Advisors first reported a position in Aldeyra Therapeutics in Q1 2015 and held it in 44 quarters.
Perceptive Advisors's Aldeyra Therapeutics position peaked at $113M in Q1 2023.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.